The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...

(RTTNews) - Antares Pharma Inc. (ATRS) announced the availability of XYOSTED or testosterone enanthate injection. XYOSTED is the only FDA approved subcutaneous testosterone product for once-weekly, at ...

EWING, N.J., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. XYOSTED™ is the only FDA approved ...

As of Dec 2019, the monthly prescription count for XYOSTED has broken past 10,000 units. This is a considerable feat considering TRT generics are available for less than 10% of the list price of ...

EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED ®, a subcutaneous ...

Shares of Antares Pharma (ATRS +0.00%) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for its testosterone treatment Xyosted. The ...

EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored ...

EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with ...

Prior to starting Xyosted, the patient's baseline cardiovascular risk should be considered and blood pressure should be adequately controlled. Antares Pharma announced the launch of Xyosted ...

Company has transitioned from a speculative play to a high-growth profitable business. Lead drug Xyosted continues phenomenal growth and promises increasingly profitable operations for the foreseeable ...

The US Food and Drug Administration (FDA) has declined to approve a new drug application (NDA) for testosterone enanthate (Xyosted, Antares Pharma) in a proprietary autoinjector and has raised two ...

EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with ...